Abstract
Background Fixed dose combinations (FDCs) are one of the options for improving blood pressure (BP) goal attainment. However, it has not been studied previously in Iraqi patients.
Objective The aim of the study is to evaluate the efficacy and tolerability of FDC valsartan/ amlodipine (Val/Aml) in a group of Iraqi hypertensive patients.
Patients and Methods One hundred and eighteen hypertensive patients were recruited from a health centre, male were 49 and female were 69 with a mean age of 49.1 years.
In patients whose BP was not controlled on previous antihypertensive therapy, FDC of Val/Aml at a dose of 160/5 mg were given, and allowed to be up titrated to 160/10 mg once daily with or without hydrochlorothiazide of 12.5–25 mg. Patients were followed for a minimum of 12 weeks. The efficacy and tolerability of this medication were studied among the study group.
Results Among the study group, 95 patients (80.50%) (P < 0.001) reached their BP target [<140/90 mmHg for uncomplicated hypertension, (<130/80 mmHg for patients with diabetes)] over the 12-week study period; 24 patients (20.33%) who failed to reach BP target [19 patients (16.1%) were lost to follow up, two patients (1.69%) discontinued their treatment due to medication side effects (one patient had lower limb edema, the other patients had dizziness) and three patients (2.54%) were non-compliant to the treatment plan].
Conclusion Treatment with the FDC Val/Aml was associated with significant reductions in systolic BP (SBP) and diastolic BP (DBP), and a significant increase in the BP control rate with an excellent tolerability profile.
Keywords
References
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981–2997.
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913.
Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009;18:308–347.
Bramlage P. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension. Expert Opin Pharmaco Ther. 2009;10:1755–1767.
Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. Eur Heart J. 2011;32:2499–2506.
Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double- blind, placebocontrolled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30:587–604.
Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–2428.
Akazawa M, Fukuoka K. Economic impact of switching to fixeddose combination therapy for Japanese hypertensive patients: a retrospective cost analysis. BMC Health Serv Res. 2013;13:124.
Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA.2010;303(20):2043–2050.
Mancia G, de Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: the task force for the management of arterial hypertension of the European Society of Hypertesnsion (ESH) and of the European Society of Cardiology (ESC).J Hypertens. 2007;25:1105–1187.
Oparil S, Lee J, Karki S, Melino M. Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. J Cardiovasc Pharmacol. 2009;54:427–436.
Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004;363(9426):2049–2051.
Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427–1431.
Smith TR, Glazer RD, Koren MJ, Wernsing M, Zhang Y. Combination therapy with amlodipine/valsartan in essential hypertension: a 52-week, randomised, open-label, extension study. Int J Clin Pract. 2010;64:1367–1374.
Hu D, Liu L, Li W. Efficacy and safety of valsartan/amlodipine single-pill combination in 11,422 Chinese patients with hypertension: an observational study. Adv Ther. 2014;31(7):762–775.
Ke YN, Huang J, Zhu JR; Valsartan/Amlodipine Single Pill Combination Study Group. Efficacy and safety of the single pill combination of valsartan 80 mg plus amlodipine 5 mg in mild to moderate essential hypertensive patients without adequate blood pressure control by monotherapy. Zhonghua Xin Xue Guan Bing Za Zhi. 2009;37:794–799.
Ke Y, Zhu D, Hong H, Zhu J, Wang R, Cardenas P, Zhang Y. Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy. Curr Med Res Opin.2010;26:1705–1713.
Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide:a randomized clinical trial. Hypertension. 2009;54:32–39.
Fogari R, Zoppi A, Mugellini A, Corradi L, Lazzari P, Preti P, Derosa G. Efficacy and safety of two treatment combinations of hypertension in very elderly patients. Arch Gerontol Geriatr. 2009;48(3):401–405.
Poldermans D, Glazes R, Kargiannis S, Wernsing M, Kaczor J, Chiang YT, Yen J, Gamboa R, Fomina I. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007;29:279–289.
RL. Exforge: a new combination to treat hypertension. Pharma Note. 2008;23:1–11.
Allemann Y, Fraile B, Lambert M, Barbier M, Ferber P, Izzo JL Jr. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the exforge in failure after single therapy (EX-FAST) study. J Clin Hypertens (Greenwich). 2008;10:185–194.
Krzesinski JM, Cohen EP. Exforge (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact.Core Evid. 2010;4:1–11.
Makani H, Bangalore S, Romero J, Htyte N, Berrios RS, Makwana H, Messerli FH. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate: a meta-analysis of randomized trials. J Hypertens. 2011;29:1270–1280.
Refbacks
- There are currently no refbacks.
Copyright (c) 2016 Journal of Pharmaceutical and Biomedical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.